Compare the evidence
Thermo Fisher vs Agilent
Compare scientific instruments, biopharma quality-control workflows and service exposure. These diversified portfolios have different product mixes; missing matched economics remain explicit.
Read horizontally within each row. Product ratings, planned capacity, completed deliveries and current financials describe different stages.
On narrow screens, scroll the comparison horizontally. Each figure keeps its period, accounting definition and source. GAAP cash flow, adjusted margins, segment gross profit and EBITDA are not interchangeable.
| Research dimension | Thermo Fisher ScientificTMO · Checked 2026-10-21 | Agilent TechnologiesA · Checked 2026-10-21 |
|---|---|---|
| Industrial role | Single-use bioprocessing equipment and scientific instruments | LC/HRMS instruments and biopharma quality-control workflows |
| Constraint to test | Sterile fluid handling and validated upstream/downstream scale-up | Reproducible analytical methods and regulated laboratory adoption |
| Reported evidence and sources | Thermo Fisher describes single-use bioreactors, mixers, chromatography and harvest systems with automation.
| Agilent launched a multi-attribute workflow combining LC/HRMS instrumentation, software, columns and standards for biopharma QC.
|
| Capacity and delivery |
|
|
| Reported economics | Not quantified in this profile. | |
| Evidence coverage | Primary-source operating or segment results; capacity evidence retains its stated stage. Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure. No quantified share of revenue attributable to the specific constraint. No evidence-strength score is assigned. | Public product or operations profile. Quantitative economic exposure has not been reviewed here. Constraint-specific revenue, pricing power and valuation are not quantified. Product relevance does not establish pure-play exposure. No quantified share of revenue attributable to the specific constraint. No evidence-strength score is assigned. |
| Counter-evidence | No separately sourced counter-evidence review is included in this baseline. The conditions below are research tests. | No separately sourced counter-evidence review is included in this baseline. The conditions below are research tests. |
| Next to monitor |
|
|
| What would weaken the case? |
|
|
Open in Excel or another spreadsheet. Each entry preserves its source, date and accounting definition; research interpretations are labeled.
How to use this comparison
Start with the constraint, inspect the dated sources, then follow the company to monitor new evidence. A documented industrial role does not establish a shortage or an attractive share price.
This comparison uses open company research checked on the dates shown. Valuation and expected returns require a separate review.